Table 2.
Baseline demographic and clinical variables of participants in study 1
| CKD | HS | P Value | |
|---|---|---|---|
| n | 32 | 12 | |
| Age, yr | 49.6 ± 15.3 | 43.4 ± 4.7 | 0.179 |
| Sex (F/M) | 18/14 | 5/7 | 0.388 |
| BMI, kg/m2 | 26.7 ± 5.3 | 23.7 ± 2.2 | 0.012 |
| eGFR, ml·min−1·1.73 m−2 | 46.2 ± 23.8 | 101.4 ± 9.7 | <0.001 |
| Systolic blood pressure, mmHg | 125 ± 15 | 125 ± 13 | 0.935 |
| Diastolic blood pressure, mmHg | 81 ± 12 | 79 ± 9 | 0.520 |
| V̇o2peak, ml·kg−1·min−1 | 26.1 ± 8.0 | 38.5 ± 9.8 | 0.002 |
| %Predicted V̇o2peak | 85.2 ± 24.3 | 109.3 ± 22.9 | 0.008 |
| V̇o2 at anaerobic threshold, ml·kg−1·min−1 | 24.3 ± 7.1 | 32.2 ± 8.9 | 0.027 |
| Maximal workload, W | 150.4 ± 53.2 | 259.6 ± 89.2 | <0.001 |
| Exercise duration, s | 398 ± 117 | 790 ± 238 | <0.001 |
| Respiratory exchange ratio | 1.36 ± 0.11 | 1.27 ± 0.09 | 0.021 |
| Resting heart rate, beats/min | 74 ± 12 | 75 ± 13 | 0.826 |
| Peak heart rate, beats/min | 154 ± 23 | 175 ± 11 | <0.001 |
| Medication, no. (%) | |||
| ACE-I | 13 (41) | 0 | 0.007 |
| ARB | 6 (18) | 0 | 0.128 |
| Statin | 13 (41) | 0 | 0.007 |
Values are means ± SD or no. (%); n, no. of subjects. CKD, chronic kidney disease; HS, healthy subjects; F, female; M, male; BMI, body mass index; eGFR, estimated glomerular filtration rate; V̇o2peak, peak oxygen uptake; V̇o2, oxygen uptake; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.